This is a working overview of Angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-06-01 and is reviewed periodically as new material appears.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
== Career == Wadden joined the University of Pennsylvania’s Department of Psychiatry as an instructor in 1981 and rose to full professor by 1994. From 1992 to 1993, he was Professor of Psychology and Director of Clinical Training at Syracuse University, where he also led the Center for Health and Behavior. Returning to Penn in 1994, he directed the Center for Weight and Eating Disorders until 2017. He was the first Albert J. Stunkard Professor in Psychiatry (2011–2021). He has also taught as Visiting Professor of Psychology at Haverford College (2013–2021) and Bryn Mawr College (2018–2019), offering courses on obesity and health psychology. In addition, he is Clinical Associate Professor at the Philadelphia College of Osteopathic Medicine. Wadden was president of The Obesity Society in 2005–2006 and has served as associate editor of its journal, Obesity (2010–2014; 2020–2025). He was also associate editor of Annals of Behavioral Medicine (1991–1993).
h = the reduced plate height count (plate height/stationary phase particle diameter) n = the reduced mobile phase linear velocity (velocity times stationary phase particle diameter/solute diffusion coefficient in the mobile phase) A, B, and C are constants related to solute flow anisotropy (eddy diffusion), molecular longitudinal diffusion, and mass transfer properties respectively. Berthod's use of the Knox equation to experimentally determine which of the proposed theories was most correct led him to the following conclusions. The flow anisotropy in micellar phase seems to be much greater than in traditional hydro-organic mobile phases of similar viscosity. This is likely due to the partial clogging of the stationary phase pores by adsorbed surfactant molecules. Raising the column temperature served to both decrease viscosity of the mobile phase and the amount of adsorbed surfactant. Both results reduce the A term and the amount of eddy diffusion, and thereby increase efficiency. The increase in the B term, as related to longitudinal diffusion, is associated with the decrease in the solute diffusion coefficient in the mobile phase, DM, due to the presence of the micelles, and an increase in the capacity factor, k¢. Again, this is related to surfactant adsorption on the stationary phase causing a dramatic decrease in the solute diffusion coefficient in the stationary phase, DS. Again an increase in temperature, now coupled with an addition of alcohol to the mobile phase, drastically decreases the amount of the absorbed surfactant.
The impact is heavy on editors, journalism and society, but we will never remain silent. Almost a thousand people work in the head office. We are far from ignoring their feelings of insecurity in their workplace. Our social rights and democracy are under unbearable pressure, and we must all fight together. From these attacks, we learned a lot of things, notably that we must always remain vigilant. Over the years, foreign media outlets also reported on the Moroccan mafia, particularly in Germany, Spain, Italy, Brazil, Colombia, Chile, Morocco, and the United Kingdom. BBC News stated in 2019 that the Netherlands was in the process of becoming a narco-state.
== Applications == Mass cytometry has research applications in medical fields including immunology, hematology, and oncology. It has been used in studies of hematopoiesis, cell cycle, cytokine expression, and differential signaling responses. MC has been used in various research fields, such as cancer biology, immunology, and neuroscience, to provide a more comprehensive understanding of tissue architecture and cellular interactions.
Sources: en.wikipedia.org
1930) 5 October – Bill Munro, 89, Scottish football player (Barrow) and manager (Clydebank, Airdrieonians). 15 October – Edward Cairney, 82, convicted murderer 16 October – Gordon Low, 83, Scottish footballer (Huddersfield Town, Bristol City, Stockport County). 18 October – David P. Webster, 95, Scottish author, historian, and sports promoter (World Highland Games Championships), complications from dementia. 20 October – Donald Angus Cameron of Lochiel, 77, Scottish clan chief and public servant, Lord Lieutenant of Inverness (2002–2021). Donald Mackay, 86, Scottish-born Canadian chemical engineer. 31 October – Hugh Wyllie, 89, Scottish Presbyterian minister, moderator of the General Assembly of the Church of Scotland (1992–1993). 6 November – John Fahy, 80, Scottish footballer (Germiston Callies, Oxford United). Norman Munnoch, 94, Scottish rugby union player (Watsonian, Edinburgh District, national team). 8 November – Dale Reid, 64, Scottish golfer. 10 November – Colin Mackay, 79, Scottish journalist. 13 November – Gordon Wallace, 74, Scottish footballer (Raith Rovers, Dundee United, Berwick Rangers). 19 November – Eddie Linden, 88, Scottish publisher and poet. 26 November – Norman Irons, 82, Scottish councillor and honorary consul, lord provost of Edinburgh (1992–1996). 28 November – James Douglas-Hamilton, Baron Selkirk of Douglas, 81, Scottish politician, MP (1974–1997), MSP (1999–2007) and member of the House of Lords (1997–2023). 30 November – John Byrne, 83, Scottish playwright (The Slab Boys Trilogy, Tutti Frutti, Your Cheatin' Heart) and designer.
k¢ is the capacity factor of the solute KSW is the partition coefficient of the solute between the stationary phase and the water KMW is the partition coefficient of the solute between the micelles and the water f is the phase volume ratio (stationary phase volume/mobile phase volume) n is the molar volume of the surfactant CM is the concentration of the micelle in the mobile phase (total surfactant concentration - critical micelle concentration) A plot of 1/k¢ verses CM gives a straight line in which KSW can be calculated from the intercept and KMW can be obtained from the ratio of the slope to the intercept. Finally, KSM can be obtained from the ratio of the other two partition coefficients:
Most children with progeria appear normal at birth and during early infancy. Children with progeria usually develop the first symptoms during their first few months of life. The earliest symptoms may include a failure to thrive and a localized scleroderma-like skin condition. As a child ages past infancy, additional conditions become apparent, usually around 18–24 months. Limited growth, full-body alopecia (hair loss), and a distinctive appearance (a small face with a shallow, recessed jaw and a pinched nose) are all characteristics of progeria. Signs and symptoms of this progressive disease tend to become more marked as the child ages. Later, the condition causes wrinkled skin, kidney failure, loss of eyesight, and atherosclerosis and other cardiovascular problems. Scleroderma, a hardening and tightening of the skin on trunk and extremities of the body, is prevalent. People diagnosed with this disorder usually have small, fragile bodies, like those of older adults. The head is usually large relative to the body, with a narrow, wrinkled face and a beak nose. Prominent scalp veins are noticeable (made more obvious by alopecia), as well as prominent eyes. Musculoskeletal degeneration causes loss of body fat and muscle, stiff joints, hip dislocations, and other symptoms generally absent in the non-elderly population. Individuals usually retain typical mental and motor function.
== Thin layer chromatography == The first developments in thin layer chromatography occurred in the 1940s, and techniques advanced rapidly in the 1950s after the introduction of relatively large plates and relatively stable materials for sorbent layers.
== Overdose == There has been no clinical experience with overdose of EMP. Overdose of EMP may result in pronounced manifestations of the known adverse effects of the medication. There is no specific antidote for overdose of EMP. In the event of overdose, gastric lavage should be used to evacuate gastric contents as necessary and treatment should be symptom-based and supportive. In the case of dangerously low counts of red blood cells, white blood cells, or platelets, whole blood may be given as needed. Liver function should be monitored with EMP overdose. After an overdose of EMP, hematological and hepatic parameters should continue to be monitored for at least 6 weeks. EMP has been used at high doses of as much as 1,260 mg/day by the oral route and 240 to 450 mg/day by intravenous injection.
Sources: en.wikipedia.org
=== Differentiation === CAFs can also be derived from differentiation of other cell types such as mesenchymal stem cells, which was proved in murine models with cancers such as glioma, breast, pancreatic and gastric cancers. Another suggested origin is differentiation of endothelial or epithelial cells via trans-differentiation or epithelial to mesenchymal transition, respectively. Less common origin of CAFs is by differentiation of other tumor adjacent cells such as epithelial or endothelial cells, adipocytes, pericytes and smooth muscle cells. Adipocytes, especially white adipocytes transdifferentiate into CAFs upon activation with TGF-β1. Through TGF-β1 can be transformed also peritoneal mesothelial cells. It has been suggested that CAFs are better conceptualised as a “cell state” Research has found that CAF trans-differentiation can be caused by epigenetic factors.
The three substrates of this enzyme are alanine, water, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are pyruvic acid, reduced NADH, ammonia, and a proton. This enzyme participates in taurine and hypotaurine metabolism and reductive carboxylate cycle (CO2 fixation).
Like the East German state newspaper, official Romanian news organs made no mention of the fall of the Berlin Wall in the first days following 9 November 1989. The most notable news in Romanian newspapers of 11 November 1989, was the "masterly lecture by comrade Nicolae Ceaușescu at the extended plenary session of the Central Committee of the Communist Party of Romania," in which the Romanian head of state and party highly praised the "brilliant programme for the work and revolutionary struggle of all our people," as well as the "exemplary fulfillment of economic tasks." What had happened 1,500 km (930 mi) northwest of Bucharest, in divided Berlin, during those days is not even mentioned. Socialism is praised as the "way of the free, independent development of the peoples." The same day, on Bucharest's Brezoianu Street and Kogălniceanu Boulevard, a group of students from Cluj-Napoca attempted a demonstration but were quickly apprehended. It initially appeared that Ceaușescu would weather the wave of revolution sweeping across Eastern Europe, as he was formally re-elected for another five-year term as General Secretary of the Romanian Communist Party on 24 November at the party's XIV Congress. On that same day, Ceaușescu's counterpart in Czechoslovakia, Miloš Jakeš, resigned along with the entire Communist leadership, effectively ending Communist rule in Czechoslovakia.
=== Management buyout and retro theming (1995–2001) === In 1995, the chain was bought from Unilever by senior management. During 1997 and 1998, Drew Carey served as a spokesperson for the chain, appearing in TV ads alongside the Great Root Bear; he was dismissed (with legal action ensuing) after a November 1998 episode of The Drew Carey Show featured Carey eating at a McDonald's location in China.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.